Brought to you by 
Cellular therapy company Rubius Therapeutics nets $257.8mm in IPO
10 Jun 2021
Executive Summary
Rubius Therapeutics Inc. (off-the-shelf cell therapies) netted $257.8mm in its upsized initial public offering of 12.055mm (including full exercise of the over-allotment) common shares (originally planned to sell 9.5mm shares at $20-$22) at $23.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cellular therapy company Rubius Therapeutics nets $257.8mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice